BÜHLMANN Laboratories AG Partners with Beckman Coulter
BÜHLMANN Laboratories AG, known for its high-quality in-vitro diagnostic products, has announced an exciting new collaboration with Beckman Coulter. This partnership aims to facilitate the worldwide distribution of the BÜHLMANN fCAL® turbo and fPELA® turbo assays. These assays will be integrated into Beckman Coulter's clinical chemistry analyzers, providing laboratories with advanced tools to enhance patient care and diagnostic precision.
Streamlining Laboratory Processes
The collaboration is set to streamline laboratory operations significantly. By employing the BÜHLMANN fCAL® turbo assay alongside the CALEX® Cap sample preparation device, laboratories can efficiently determine fecal inflammation and digestion markers. This integration allows laboratories to automate their workflows more comprehensively, thus reducing manual processes and potential errors.
The BÜHLMANN fCAL® turbo Assay
The FDA-cleared BÜHLMANN fCAL® turbo assay is designed specifically to measure fecal calprotectin levels, a critical marker for diagnosing inflammatory bowel disease (IBD). This test stands out for its rapid results and high-quality analytical performance. Clinical studies have validated its effectiveness in distinguishing between IBD and irritable bowel syndrome (IBS), showcasing its precision and reliability.
Technological Advancements in Diagnostics
With technological innovation at the forefront, the fCAL® turbo assay enables clinicians to obtain results promptly, thereby aiding timely diagnosis and treatment. This responsiveness can greatly influence patient management, particularly in conditions that require quick intervention.
The BÜHLMANN fPELA® turbo Assay
On the other hand, the FDA-exempt BÜHLMANN fPELA® turbo assay provides an automated method for quantifying pancreatic elastase in stool samples. This biomarker is crucial for diagnosing exocrine pancreatic insufficiency, particularly in patients with chronic pancreatitis. By measuring pancreatic elastase levels, clinicians can better assess pancreatic function and the overall health of their patients.
Improving Patient Outcomes
Both assays significantly improve clinical efficiency while ensuring reproducibility and precision in results. This partnership not only supports the ongoing demand for accurate diagnostic tools but also reflects BÜHLMANN's commitment to enhancing laboratory capabilities worldwide.
A Commitment to Excellence
Laurent Collignon, CEO of BÜHLMANN Laboratories AG, expressed the company’s enthusiasm for this collaboration. He emphasized how the BÜHLMANN fCAL® turbo assay is prepared to meet the increasing demands in laboratory settings, offering unmatched throughput and speed in obtaining results.
Support and Training for Seamless Integration
Collin Shaw, CEO of BUHLMANN Diagnostics Corp, added that the collaboration would enhance customer support and training. This commitment ensures that laboratory staff can seamlessly adopt and integrate these advanced assays into their daily operations, ultimately benefiting patient diagnostics.
About BÜHLMANN Laboratories AG
Founded in 1976, BÜHLMANN Laboratories AG is a mid-sized company based in Switzerland, dedicated to developing and distributing high-quality in-vitro diagnostics. With a global presence spanning over 60 distributors, BÜHLMANN focuses on providing specialized diagnostic solutions while prioritizing quality and innovation.
About BUHLMANN Diagnostics Corp
As the U.S. commercial affiliate of BÜHLMANN Laboratories AG, BUHLMANN Diagnostics Corp operates out of Amherst, NH, and is dedicated to offering superior sales and support services to clinical laboratories across the country.
Frequently Asked Questions
What is the purpose of the BÜHLMANN fCAL® turbo assay?
The BÜHLMANN fCAL® turbo assay is designed to measure fecal calprotectin, aiding in the diagnosis of inflammatory bowel disease (IBD).
How does the collaboration with Beckman Coulter benefit laboratories?
This collaboration streamlines laboratory workflows by facilitating the automated integration of BÜHLMANN assays into Beckman Coulter's analyzers.
What is the role of pancreatic elastase in diagnosis?
Pancreatic elastase is a biomarker used to assess pancreatic function and is crucial for diagnosing exocrine pancreatic insufficiency.
Where is BÜHLMANN Laboratories AG located?
BÜHLMANN Laboratories AG is located in Schönenbuch, Switzerland, near Basel.
What kind of support will be provided to laboratories?
BUHLMANN Diagnostics Corp offers extensive training and support to facilitate the adoption of the new assays, ensuring laboratories can integrate them smoothly.
